ReviewArchives of virology2026
The role of DPP4 in viral infections: from receptor biology to antiviral target.
Review in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Dipeptidyl Peptidase 4 (DPP4) is a type II transmembrane serine protease with diverse physiological roles in metabolic regulation and immune modulation. Beyond its native functions, DPP4 has emerged as a critical host factor exploited by a range of viruses to drive infection and pathogenesis. This review synthesizes the multifaceted interactions between DPP4 and viral pathogens. We examine the structural basis for direct receptor binding by coronaviruses such as MERS and PHEV, as well as the dual-receptor entry mechanism used by human astroviruses. Additionally, the review explores how viruses such as HIV-1 and HCV exploit DPP4's enzymatic and non-enzymatic functions to modulate T cell activation and promote viral persistence. Finally, we evaluate pharmacological perspectives, including DPP4 inhibitors, monoclonal antibodies, and soluble decoy receptors as host-directed therapies. By mapping these diverse viral strategies, this article provides a comprehensive framework for understanding DPP4 as a moonlighting protein and a promising target for broad-spectrum antiviral interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.